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Background: Administrative claims are an important data source for COPD research but lack a
validated measure of patient COPD severity, which is an important determinant of treatment
and outcomes.
Methods: Patients with1 diagnosis of COPD and spirometry results from 01/2004-05/2011were
identified from an electronic health records database linked to healthcare claims. Patients were
classified into 3 COPD severity groups based on spirometry and Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines: GOLD-Unclassified, Mild/Moderate, and Severe/
Very Severe. A multinomial logistic regression model was constructed using claims data from 3
months before and after (observation period) the most recent spirometry (index date) to cate-
gorize patient COPD severity. A random selection of 90% of patients in each severity level was
selected to build themodel, and the remaining 10% were used as a validation sample. Model pre-
dictions were evaluated for sensitivity, specificity, accuracy, and concordance.
Results: Among 2028 COPD patients who met sample selection criteria, 886, 683, and 459 pa-
tients were in the GOLD-Unclassified, Mild/Moderate, and Severe/Very Severe categories,
respectively. The final model included age, sex, comorbidities (such as pulmonary fibrosis andCOPD, chronic obstructive pulmonary disease; ER, emergency room; EHR, electronic health record;
ne second; FVC, forced vital capacity; GHP, Geisinger Health Plan; GHS, Geisinger Health System;
structive Lung Disease; ICD-9, International Classification of Diseases, Ninth revision.
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Claims-based prediction model for COPD severity 1569diabetes), COPD-related resource utilization (such as oxygen use), and all-cause healthcare uti-
lization. In the validation sample, the model correctly predicted COPD severity for 62.7% of all
patients (accuracy for predicting GOLD-Unclassified: 73.5%; Mild/Moderate: 70.6%; Severe/Very
Severe: 81.4%) with kappaZ 0.41.
Conclusions: The prediction model was developed using clinically measured COPD severity to
provide researchers an approach to classify patients using claims data when clinical measures
are not available.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease characterized by persistent airflow
obstruction to the lungs that is not fully reversible [1].
COPD affects over 24 million American adults [2] and costs
approximately $50 billion per year [3]. Given its substantial
disease burden, administrative claims are a valuable data
source for studying real-world COPD-related economic and
health outcomes for large populations, providing rich data
on treatment patterns, costs, and healthcare utilization.
For claims analyses, measuring disease severity plays a
critical role in accurately characterizing samples, per-
forming statistically valid comparisons, and serving as a
study outcome. The Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) guidelines suggest classifying
COPD severity based on spirometry e specifically, the
forced expiratory volume for one second (FEV1) and the
proportion of the forced vital capacity exhaled in the first
second (FEV1/FVC) [1]. The classification of COPD severity
via spirometry is important as it constitutes the basis of
treatment recommendations [1] and corresponds to signif-
icant differences in health outcomes [4e8]. However, since
clinically measured COPD severity is not observable in
claims data, claims studies use a wide range of proxies for
COPD severity, including comorbidities and evidence of
COPD exacerbations [9,10]. Reliance on proxy measures
rather than clinical spirometric data to define COPD
severity may be less accurate.
The objective of this study is to use clinically measured
COPD severity to develop a claims-based method, which
can be used to predict patient severity when pulmonary
function data is unavailable. A COPD severity measure
developed using clinical data and information readily
available in claims as predictors may prove useful when
examining COPD in future claims analyses.Materials and methods
Data source
This study used de-identified data from the Geisinger
Health System (GHS), an integrated health system in
Pennsylvania comprising over 700 multi-specialty physi-
cians, 3 hospitals, 40 ambulatory clinics, and 3 research
centers, which also offers insurance coverage through the
Geisinger Health Plan (GHP). GHS database has a cumula-
tive patient base of approximately 3 million lives and in-
cludes linked EHR and GHP claims data. This study usedlinked data from January 2004 to May 2011 for patients with
GHP insurance, who account for approximately 50% of all
patients in the EHR data. Claims data capture both in-
network and out-of-network (outside GHS) resource use and
include medical, hospital, and pharmacy claims for GHP
members. EHR pulmonary function test results from
spirometry included actual, predicted (based on patient’s
age and sex), and percent predicted values (actual/
predicted  100) for FEV1, FVC, and FEV1/FVC ratio.
Study design and sample
Patients were retrospectively selected if they had a
recorded COPD diagnosis (International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9] codes
491 [chronic bronchitis], 492 [emphysema], or 496 [chronic
airway obstruction]) and EHR results from at least one
spirometry test.
For each patient, the most recent spirometry result
meeting the following criteria was selected. First, tests
with claims data available both 3 months prior to and
following were selected. The 3-month post-period was
included to capture medication use and treatment
following a test, which would likely be associated with
COPD severity. Second, in this 6-month window, patients
were required to have continuous eligibility in GHP to
ensure complete resource utilization information, which
excluded patients who potentially died during the obser-
vation period, and no recorded asthma diagnoses (ICD-9
code 493) to safeguard against potential misdiagnosis of
asthma. Third, spirometry within 1 week of a COPD exac-
erbation were excluded, as GOLD guidelines categorize
severity in reference to a patient’s baseline severity.
Spirometry during an exacerbation may overstate a pa-
tient’s underlying severity and can be difficult for a sick
patient to perform properly, leading to an inaccurate
measurement [1]. COPD exacerbations were identified
using a modified version of the algorithm developed by
Mapel et al. [10] (e-Appendix 1). If multiple tests were
eligible, the most recent spirometry test was selected.
Alternatively, choosing the test with the most severe
reading among all eligible tests was considered but had no
effect on the severity distribution. The 6-month window e
3 months before and after the selected spirometry test e
was defined as the observation period.
COPD severity
Patients were categorized into 4 COPD severity levels (Mild,
Moderate, Severe, Very Severe) based on GOLD guidelines
1570 D. Macaulay et al.(e-Appendix 2) [1]. Patients diagnosed with COPD who
could not be categorized into one of the GOLD categories
(FEV1/FVC  0.70) were defined as “GOLD-Unclassified”.
This separate category was created because, while severity
was unidentified by spirometry, it was important to include
all COPD-diagnosed patients with a spirometry reading, as
these patients would likely be observed in a typical claims
database. “GOLD-Unclassified” patients may include those
misdiagnosed with other lung conditions, such as pulmonary
fibrosis, or COPD patients unable to complete the test
because of obesity, which limits the diaphragm’s ability to
displace intra-abdominal fat [11]. After classifying patients
into these categories, the 5 categories were collapsed into
3 levels e GOLD-Unclassified, Mild/Moderate, and Severe/
Very Severe to ensure a reasonable number of patients in
each category.
Patient characteristics potentially associated with
severity
Patient demographics (e.g., age, gender), medical condi-
tions (e.g., pulmonary vascular disease, osteoporosis), and
all-cause and COPD-related healthcare utilization poten-
tially associated with COPD and readily available in claims
were selected based on literature review and clinical
expert opinion (e-Appendix 3). COPD-related utilization
during the 6-month observation period was defined as: an
inpatient, emergency room (ER), or outpatient visit with a
COPD diagnosis; COPD exacerbation; and COPD medications
(e.g., inhaled corticosteroids, short-acting beta-agonists)
(e-Appendix 4). COPD-related procedures during the 6-
month observation period were also evaluated (e-
Appendix 5), including: surgery (e.g., lung volume reduc-
tion), pulmonary rehabilitation, and oxygen therapy. These
variables were descriptively estimated and compared
across the 3 severity levels using pairwise comparisons with
the GOLD-Unclassified group.
Model construction
A random selection of 90% of patients in each severity level
(training sample) was used to develop the model, and the
remaining 10% (validation sample) served to validate theTable 1 Sample selection of chronic obstructive pulmonary dis
Step Description
1 Patients with at least one diagnosis of COPD in the claim
2 Patients with at least one FEV1 (actual) measure
3 Patients continuously enrolled in Geisinger Health Plan (
4 Patients with no history of asthma during these periodsc
5 Patients with at least one spirometry test not taken with
COPD-related antibiotic or steroid used
COPDZ chronic obstructive pulmonary disease; EHRZ electronic hea
vital capacity; ICD-9 Z International Classification of Diseases, 9th re
a COPD was defined by the ICD-9 codes of 491, 492, and 496.
b The observation period consisted of the 90 days prior to and the 9
c Asthma was defined by the ICD-9-CM code of 493.
d Refer to e-Appendix 1 for the algorithm to identify COPD exacerba
Ref. [1].model. Univariable multinomial logistic regressions, with
the observed COPD severity level as the dependent vari-
able, were performed on the training sample to assess the
association between each potential predictor and COPD
severity. Each predictor with p < 0.50 for any of the
severity categories was included as a potential covariate
for the multivariable model.
After the univariable selection of potential predictors, a
multivariable multinomial logistic regression model was
constructed using the observed COPD severity category as
the dependent variable and measures identified in the uni-
variable analysis as potential predictors. Stepwise selection
(with threshold p< 0.50) was applied to identify the final set
of predictors. For each patient, the probability of being
assigned into each COPD severity category was predicted
using the multivariable model. Each patient was classified in
the category with the highest predicted probability.
Predictive performance
For all patients in the validation sample, the patients’
predicted and observed COPD severity categories were
compared. Sensitivity (e.g., proportion of patients with
Severe/Very Severe COPD classified as having Severe/Very
Severe COPD by the model), specificity (e.g., proportion of
patients without Severe/Very Severe COPD classified as not
having Severe/Very Severe COPD by the model), and ac-
curacy (i.e., proportion of patients classified to their true
COPD severity categories) were estimated to assess the
model’s performance. Concordance statistics (Cohen’s
Kappa) were estimated to evaluate the agreement between
predicted and observed categories. Performance of the
model was similarly assessed for the training sample.
All analyses were performed in SAS version 9.2 (SAS
Institute Inc., Cary, NC).Results
Patient characteristics
Among patients with a recorded COPD diagnosis and avail-
able EHR data, 2028 patients met all the selection criteriaease patients with FEV1 (actual) spirometry.
Number of patients
s historya and available EHR data 29,373
4138
GHP) during the observation periodb 3089
2428
in 1 week of a COPD exacerbation or 2028
lth record; FEV1Z forced expiratory volume in 1 s; FVCZ forced
vision, Clinical Modification.
0 days following the test.
tions and/or COPD-related antibiotic or steroid use, adapted from
Claims-based prediction model for COPD severity 1571and were included in the final sample (Table 1). Out of the
2028 patients, 886 were categorized as GOLD-Unclassified,
683 as Mild/Moderate, and 459 as Severe/Very Severe. A
total of 1824 patients were randomly selected for the
training sample, leaving 204 patients in the validation
sample. Based on a descriptive assessment of patient
characteristics, compared to the GOLD-Unclassified cate-
gory, the Mild/Moderate and Severe/Very Severe categories
had a higher proportion of male patients, higher average
age, and more COPD-related resource use (Tables 2e4).
More evidence of obesity and pulmonary fibrosis was
observed for GOLD-Unclassified patients than those with a
known level of COPD severity, which is consistent with
previous literature [11].
Prediction model
The final prediction model included demographics, medical
conditions, COPD-related resource utilization, and all-
cause healthcare visits as predictors of three COPD
severity categories (Table 5). More severe COPD was posi-
tively associated with being male and older. Osteoporosis
was positively associated with COPD severity; whereas,
pulmonary fibrosis, skeletal muscle dysfunction, and
obesity were negatively associated with COPD severity.
COPD-related ER, inpatient, and outpatient visits and oxy-
gen therapy were positively associated with COPD severity.
Other potential predictors of COPD severity, such as respi-
ratory infection, pulmonary vascular disease, and pneu-
monia, did not demonstrate an association (i.e., did not
have a p-value <0.50) so they were not included in the final
model.
In the validation sample, the model correctly predicted
COPD severity for 62.7% of all patients (kappaZ 0.41), with
sensitivity of 77.5%, 52.2%, and 50.0% for GOLD-
Unclassified, Mild/Moderate, and Severe/Very Severe pa-
tients, respectively. Corresponding specificities of the
model were 70.4%, 80.0%, and 90.5%, suggesting that the
model is highly specific for the Severe/Very Severe category
and fairly specific for the Mild/Moderate category. The
accuracies were 73.5%, 70.6%, and 81.4% for the GOLD-
Unclassified, Mild/Moderate, and Severe/Very Severe pa-
tients, respectively, demonstrating fairly high accuracy for
all 3 categories. Positive predictive values (PPVs) for the
three categories were 67.0%, 57.1% and 60.4% and negative
predictive values (NPVs) for the three categories were
80.1%, 76.6% and 86.2%, respectively. Predictive perfor-
mance for the training sample demonstrated similar results
(Table 6).
Discussion
This study used linked claims and EHR data to develop and
validate a claims-based algorithm to predict COPD severity.
The validated, claims-based severity categories enable re-
searchers using claims data to predict COPD severity in the
absence of clinical measures. The algorithm was built using
a sample of patients at GHS, a primarily rural, tertiary care
center.
The predictive performance of the model suggests that
the selected variables provide a reasonable way todifferentiate patient severity in future claims analyses.
Approximately 63% of patients were correctly categorized
by the prediction model. In a null model, with patients
randomly classified into one of 3 categories, approximately
33% would be correctly categorized, with sensitivities of
33%, specificities of 67%, and accuracies between 52% and
59%. The proposed model performs better than the null
model for patients in all categories and particularly for
Severe/Very Severe COPD (specificity of 90.5%). In other
words, when applying the prediction model to select Se-
vere/Very Severe patients from a claims dataset, patient
categorization is fairly reliable. Moreover, the high sensi-
tivity of the model in predicting patients in the GOLD-
Unclassified category (77.5%) shows that the model per-
forms well in correctly identifying these difficult-to-classify
patients.
Administrative claims databases are an important source
of real-world population-based data for epidemiological,
health economics, and outcomes research. Claims data
offer a way to assess mortality rates for different COPD
populations as well as provide healthcare utilization and
cost data to study its economic burden. However, COPD
severity information is often needed to accurately charac-
terize study populations. For example, if not adequately
taken into account, disease severity may confound com-
parisons of costs or COPD exacerbation rates across two
treatment groups.
Claims-based prediction models are often used to pre-
dict disease severity in other diseases such as breast cancer
[12], lung cancer [13], and asthma [14]. These studies
found similar levels of performance for their prediction
models. The current study provides a prediction model that
can be used on typical claims data to estimate patients’
COPD severity with reasonable accuracy, thus ensuring ac-
cess to this crucial variable.
Previous severity algorithms have been constructed for
use with clinical or survey data and cannot be directly
applied to a claims dataset. In a recent study, Goossens
et al. [15] developed an algorithm for COPD severity based
on data available from a large respiratory clinical trial of
moderate to severe COPD patients. The model was built
using observed GOLD severity for all patients, who all had a
classifiable COPD severity level. The predictors in this
model included demographics (age, sex), body mass index
(BMI), smoking history, COPD-related therapies, osteopo-
rosis, and hospital admission in the previous year. Although
our study shares several similarities, the Goossens et al.
model’s performance was worse than our model (un-
weighted kappaZ 0.151 vs. 0.41). It should be noted that,
unlike our model, the Goosens et al. model cannot be
applied to a typical claims dataset because clinical in-
dicators such as BMI and smoking history are not available in
claims. Further, some patients diagnosed with COPD will
not have classifiable COPD severity (GOLD-Unclassified);
however, the Goosens et al. model does not address this
population. Our current model included the GOLD-
Unclassified category, thus providing an effective method
to identify this patient group in claims. Other survey-based
studies have developed similar tools to determine COPD
severity using clinical and patient-reported measures not
usually available in claims data [16e19]. The prediction
model reported here attempts to provide a potential
Table 2 Patient characteristics potentially associated with disease severity (demographics, comorbidities, therapies, and
exacerbations).a
Observed COPD severity category
GOLD-Unclassified
N Z 886
Mild/Moderate
N Z 683
Severe/Very Severe
N Z 459
Demographics
Age on index date,b mean (SD) 67.4 (12.5) 69.9 (11.2)* 70.0 (10.0)*
Male, N (%) 463 (52.3%) 447 (65.4%)* 297 (64.7%)*
Spirometry test results
FEV1 predicted 79.2 (18.4) 69.0 (14.1)* 36.2 (9.3)*
FEV1/FVC 78.5 (5.7) 61.5 (6.6)* 46.9 (11.7)*
Comorbidities, N (%)
Respiratory related
Respiratory infection 223 (25.2%) 156 (22.8%) 136 (29.6%)
Respiratory distress 366 (41.3%) 195 (28.6%)* 140 (30.5%)*
Pulmonary vascular disease 135 (15.2%) 74 (10.8%)* 62 (13.5%)
Pulmonary fibrosis 101 (11.4%) 37 (5.4%)* 18 (3.9%)*
Acute respiratory failure 28 (3.2%) 5 (0.7%)* 23 (5.0%)
Asphyxia and respiratory arrest 101 (11.4%) 50 (7.3%)* 80 (17.4%)*
Pneumonia 94 (10.6%) 70 (10.2%) 75 (16.3%)*
Lung cancer 53 (6.0%) 58 (8.5%) 32 (7.0%)
Thoracic malignancies 56 (6.3%) 60 (8.8%) 33 (7.2%)
Cardiovascular related
Hypertension 547 (61.7%) 400 (58.6%) 279 (60.8%)
Heart failure 196 (22.1%) 130 (19.0%) 112 (24.4%)
Ischemic heart disease 345 (38.9%) 268 (39.2%) 169 (36.8%)
Cerebrovascular accident 159 (17.9%) 117 (17.1%) 58 (12.6%)*
Angina 75 (8.5%) 50 (7.3%) 14 (3.1%)*
Other COPD comorbidities
Diabetes 269 (30.4%) 141 (20.6%)* 117 (25.5%)
Weight loss 28 (3.2%) 18 (2.6%) 17 (3.7%)
Nutritional abnormalities 46 (5.2%) 25 (3.7%) 25 (5.4%)
Skeletal muscle dysfunction 91 (10.3%) 58 (8.5%) 24 (5.2%)*
Osteoporosis 108 (12.2%) 83 (12.2%) 82 (17.9%)*
Bone fractures 31 (3.5%) 26 (3.8%) 14 (3.1%)
Depression 130 (14.7%) 69 (10.1%)* 58 (12.6%)
Anemia 194 (21.9%) 136 (19.9%) 90 (19.6%)
Glaucoma 84 (9.5%) 43 (6.3%)* 37 (8.1%)
Acute renal failure 43 (4.9%) 29 (4.2%) 12 (2.6%)*
Chronic renal failure 105 (11.9%) 101 (14.8%) 54 (11.8%)
Obesity and its comorbidities
Obesity 114 (12.9%) 37 (5.4%)* 46 (10.0%)
Cholelithiasis (gallstones) 37 (4.2%) 20 (2.9%) 8 (1.7%)*
Osteoarthritis 200 (22.6%) 116 (17.0%)* 61 (13.3%)*
Low back pain 67 (7.6%) 45 (6.6%) 16 (3.5%)*
Gastroesophageal reflux disease 194 (21.9%) 124 (18.2%) 80 (17.4%)
Obstructive sleep apnea 92 (10.4%) 41 (6.0%)* 35 (7.6%)
Pulmonary embolism 34 (3.8%) 13 (1.9%)* 14 (3.1%)
Non-alcoholic fatty liver disease 16 (1.8%) 4 (0.6%)* 8 (1.7%)
Procedures and therapies
Patients with at least one procedure/therapy, N (%)
Lung volume reduction surgery 26 (2.9%) 17 (2.5%) 7 (1.5%)
Pulmonary rehabilitation 1 (0.1%) 4 (0.6%) 8 (1.7%)*
Oxygen therapy 158 (17.8%) 117 (17.1%) 224 (48.8%)*
Ventilation 76 (8.6%) 34 (5.0%)* 28 (6.1%)
Number of procedures/therapies, mean (SD)
Lung volume reduction surgery 0.0 (0.2) 0.0 (0.2) 0.0 (0.2)
Pulmonary rehabilitation 0.0 (0.2) 0.1 (0.9) 0.2 (1.8)*
Oxygen therapy 1.4 (3.4) 1.4 (3.5) 4.6 (5.4)*
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Table 2 (continued )
Observed COPD severity category
GOLD-Unclassified
N Z 886
Mild/Moderate
N Z 683
Severe/Very Severe
N Z 459
Ventilation 0.5 (1.8) 0.3 (1.4)* 0.3 (1.6)
Exacerbation of COPDc
Patients with at least one episode, N (%) 218 (24.6%) 182 (26.6%) 161 (35.1%)*
Number of episodes, mean (SD) 0.3 (0.6) 0.4 (0.7) 0.5 (0.8)*
COPD Z chronic obstructive pulmonary disease; GOLD Z Global Initiative for Chronic Obstructive Lung Disease; ICD-9 Z International
Classification of Diseases, 9th revision, Clinical Modification; SD Z standard deviation.
a Chi-square test or Fisher’s exact test if any expected cell count was less than five was used to compare categorical variables.
Wilcoxon rank-sum test was used to compare continuous variables. All p-values were based on the pairwise comparison to the “GOLD-
Unclassified” group. p-values less than 0.05 were marked with asterisks.
b Index date was defined as the date of the spirometry test.
c COPD exacerbation was defined as any of the following events in the observation period: an inpatient hospital stay or an emergency
room visit associated with a primary diagnosis of COPD (first-position ICD-9 codes 491, 492, 496); or an outpatient visit with any of the
following ICD-9 codes in the first position: 136.3, 466e466.19, 480e486, 487.0, 490, 491.21, 491.22, 494.1, 506.0e506.3, 507,
511.0e511.1, 512, 517.1, 518.0, 518.81, 518.82 and 518.84. Adapted from: Mapel et al.[10]
Claims-based prediction model for COPD severity 1573solution in cases where such clinical measures are not
readily available.
Other studies have developed COPD severity scores in
the absence of lung function data; however, none have
been validated against clinical measures [10,20e26]. For
example, Wu et al. [9] developed a severity score based on
measures available in claims data using principal compo-
nents analysis, but their proxy score has not been validated
against clinical measures of COPD severity. Mapel et al.
classified COPD complexity using comorbid respiratoryTable 3 Patient characteristics potentially associated with dise
Observed COPD seve
GOLD-Unclassified
N Z 886
Healthcare utilization
Patients with at least one visit, N (%)
Outpatient 885 (99.9%)
ER 226 (25.5%)
Inpatient 213 (24.0%)
COPD-related outpatientb 19 (2.1%)
COPD-related ERb 398 (44.9%)
COPD-related inpatientb 23 (2.6%)
Number of visits, mean (SD)
Outpatient 13.8 (9.0)
ER 0.4 (0.7)
Inpatient 0.3 (0.7)
COPD-related outpatientb 0.8 (1.2)
COPD-related ERb 0.0 (0.2)
COPD-related inpatientb 0.0 (0.2)
COPDZ chronic obstructive pulmonary disease; ERZ emergency room
ICD-9 Z International Classification of Diseases, 9th revision, Clinical
a Chi-square test or Fisher’s exact test if any expected cell count
Wilcoxon rank-sum test was used to compare continuous variables. A
Unclassified" group. p-values less than 0.05 were marked with asteris
b COPD-related outpatient visit, ER visit, and inpatient hospitalizati
hospital stay, respectively, associated with a primary diagnosis of COconditions and medical procedures [10]. In the current
study, spirometry results linked to claims data allows for
the assessment of the claims-based prediction model using
a clinical measure of COPD severity.Limitations
First, the model was constructed using patients with
spirometry reported in the EHR; however, patients withase severity (healthcare utilization).a
rity category
Mild/Moderate
N Z 683
Severe/Very Severe
N Z 459
682 (99.9%) 459 (100.0%)
138 (20.2%)* 120 (26.1%)
134 (19.6%)* 110 (24.0%)
23 (3.4%) 53 (11.5%)*
468 (68.5%)* 392 (85.4%)*
25 (3.7%) 39 (8.5%)*
12.3 (8.5)* 12.0 (8.0)*
0.3 (0.8)* 0.4 (0.7)
0.2 (0.6)* 0.3 (0.6)
1.5 (1.7)* 2.8 (2.4)*
0.0 (0.3) 0.1 (0.5)*
0.0 (0.2) 0.1 (0.4)*
; GOLDZ Global Initiative for Chronic Obstructive Lung Disease;
Modification; SD Z standard deviation.
was less than five was used to compare categorical variables.
ll p-values were based on the pairwise comparison to the "GOLD-
ks.
on was defined as an outpatient visit, an ER visit, or an inpatient
PD (first-position ICD-9 codes 491, 492, 496).
Table 4 Patient characteristics potentially associated with disease severity (percent of patients with medications).a
Observed COPD severity category
GOLD-Unclassified
N Z 886
Mild/Moderate
N Z 683
Severe/Very Severe
N Z 459
Medications
Patients with at least one drug claim, N (%)
Any of the following drugs 355 (40.1%) 345 (50.5%)* 306 (66.7%)*
b2-agonists
Short-acting
Levalbuterol 4 (0.5%) 1 (0.1%) 9 (2.0%)*
Salbutamol 147 (16.6%) 157 (23.0%)* 167 (36.4%)*
Long-acting
Formoterol 1 (0.1%) 5 (0.7%) 7 (1.5%)*
Arformoterol 1 (0.1%) 1 (0.1%) 2 (0.4%)
Salmeterol 17 (1.9%) 24 (3.5%) 36 (7.8%)*
Anticholinergics
Short-acting
Ipratropium bromide 41 (4.6%) 34 (5.0%) 59 (12.9%)*
Long-acting
Tiotropium 84 (9.5%) 135 (19.8%)* 158 (34.4%)*
Combination short-acting b2-agonists plus anticholinergic in one inhaler
Salbutamol/ipratropium 66 (7.4%) 81 (11.9%)* 84 (18.3%)*
Methylxanthines
Theophylline 0 (0.0%) 5 (0.7%)* 14 (3.1%)*
Inhaled glucocorticosteroids
Beclomethasone 0 (0.0%) 1 (0.1%) 1 (0.2%)
Budesonide 11 (1.2%) 12 (1.8%) 14 (3.1%)*
Fluticasone propionate 35 (4.0%) 43 (6.3%)* 47 (10.2%)*
Combination long-acting b2-agonists plus glucocorticosteroids in one inhaler
Formoterol/budesonide 10 (1.1%) 12 (1.8%) 14 (3.1%)*
Salmeterol/fluticasone propionate 69 (7.8%) 101 (14.8%)* 113 (24.6%)*
Systemic glucocorticosteroids
Prednisone 121 (13.7%) 106 (15.5%) 112 (24.4%)*
Methylprednisolone 12 (1.4%) 10 (1.5%) 8 (1.7%)
COPD Z chronic obstructive pulmonary disease; GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
a Wilcoxon rank-sum test was used to compare continuous variables. All p-values were based on the pairwise comparison to the “GOLD-
Unclassified” group. p-values less than 0.05 were marked with asterisks.
1574 D. Macaulay et al.spirometry may be different than those without, poten-
tially limiting the usefulness of this model for a wider
population. Thus, this prediction model is best applied in
claims analyses focusing on patients with spirometry. In
this study, approximately 14% of COPD patients with EHR
data had spirometry, but this is not a limitation of the EHR
data, as 88.3% of all patients with spirometry tests recor-
ded in their claims data have corresponding EHR results
available. While spirometry is recommended to clinically
diagnose COPD, a study by Han et al. [27] also found low
spirometry use e less than one-third of newly diagnosed
patients had spirometry e and its use for newly diagnosed
COPD decreased with age. This study is also subject to the
quality of the spirometry tests, which can sometimes be
inaccurate [28].
Second, although asthma is a potential comorbidity
associated with COPD, patients with asthma diagnoses
were excluded from the study sample to reduce the po-
tential of misdiagnosis. A number of respiratory disease
studies suggest excluding patients with overlappingdiagnoses (both asthma and COPD) when one of these two
diseases are being studied [15,29] because clinicians
might face confusion as to how and if they should differ-
entiate these two diseases [30]. A recent study by Hardin
et al. suggests that patients with both COPD and asthma
may incur more frequent exacerbations compared to pa-
tients with COPD only; however, they found that the
presence of asthma was not associated with a significant
difference in lung function [31]. This selection criterion
eliminated 566 patients (approximately 22%) from the
final sample. It is likely that some of the measures
selected for the final model would change if these pa-
tients had been included, and our model may not be
applicable to COPD patients with comorbid asthma. Third,
this study used specific ICD-9 codes to identify COPD and
its associated conditions, which may differ from those
used in future studies. For example, we did not use the
ICD-9 code 490 to define COPD. This code is often viewed
as lacking specificity for COPD, which increases the po-
tential for misclassification [32,33].
Table 5 Results of the multinomial logit regression on COPD severity.
Explanatory variables Mild/Moderatea Severe/Very Severea
Odds ratio 95% CIb Odds ratio 95% CIb
Demographics
Age on index date (continuous) 1.02 (1.01, 1.03)* 1.02 (1.01, 1.03)*
Male (categorical) 1.89 (1.50, 2.39)* 2.38 (1.76, 3.22)*
Comorbidities
Respiratory distress (categorical) 0.67 (0.53, 0.84)* 0.65 (0.48, 0.87)*
Pulmonary fibrosis (categorical) 0.40 (0.26, 0.62)* 0.14 (0.07, 0.27)*
Acute respiratory failure (categorical) 0.38 (0.14, 1.06) 2.08 (0.91, 4.75)
Asphyxia and respiratory arrest (categorical) 0.76 (0.49, 1.18) 0.74 (0.46, 1.17)
Lung cancer/Thoracic malignancies (categorical) 1.61 (0.99, 2.63) 1.55 (0.83, 2.88)
Cerebrovascular accident (categorical) 1.05 (0.78, 1.43) 0.73 (0.49, 1.10)
Angina (categorical) 0.94 (0.62, 1.43) 0.28 (0.14, 0.57)*
Nutritional abnormalities (categorical) 1.00 (0.58, 1.73) 1.91 (1.00, 3.65)*
Skeletal muscle dysfunction (categorical) 0.93 (0.63, 1.37) 0.40 (0.23, 0.69)*
Osteoporosis (categorical) 1.35 (0.95, 1.91) 2.04 (1.35, 3.09)*
Bone fractures (categorical) 1.46 (0.80, 2.67) 0.68 (0.30, 1.53)
Glaucoma (categorical) 0.64 (0.42, 0.97)* 1.06 (0.65, 1.73)
Renal failure (categorical) 1.56 (1.12, 2.19)* 0.93 (0.60, 1.44)
Diabetes (categorical) 0.55 (0.42, 0.72)* 0.67 (0.49, 0.93)*
Obesity-related condition (categorical)c 0.66 (0.52, 0.82)* 0.48 (0.36, 0.64)*
COPD exacerbation (categorical) 1.20 (0.90, 1.60) 0.95 (0.66, 1.38)
Procedures and therapies
Lung volume reduction surgery (categorical) 0.85 (0.39, 1.87) 0.32 (0.10, 1.00)*
Oxygen therapy (categorical) 1.08 (0.77, 1.52) 4.51 (3.17, 6.41)*
Ventilation (categorical) 0.78 (0.49, 1.24) 0.72 (0.41, 1.27)
Medicationsd
Short-acting b2-agonist (categorical) 1.16 (0.86, 1.56) 1.68 (1.20, 2.36)*
Long-acting b2-agonist (categorical) 1.32 (0.67, 2.58) 2.09 (1.04, 4.20)*
Short-acting anticholinergics (categorical) 0.84 (0.50, 1.42) 1.48 (0.87, 2.52)
Long-acting anticholinergics (categorical) 1.64 (1.16, 2.33)* 2.32 (1.58, 3.41)*
Combination short-acting b2-agonist plus
anticholinergic in one inhaler (categorical)
1.35 (0.93, 1.97) 1.88 (1.24, 2.86)*
Inhaled glucocorticosteroids (categorical) 1.17 (0.72, 1.89) 0.78 (0.45, 1.35)
Combination long-acting b2-agonist plus
glucocorticosteroids (categorical)
1.52 (1.06, 2.18)* 1.69 (1.14, 2.52)*
Utilization variables
All-cause ER visit (categorical) 0.88 (0.66, 1.18) 1.26 (0.87, 1.84)
All-cause inpatient visit (categorical) 0.99 (0.72, 1.36) 1.50 (1.00, 2.25)
Number of all-cause outpatient visits (continuous) 0.98 (0.97, 1.00)* 0.97 (0.96, 0.99)*
COPD-related ER visit (categorical) 1.46 (0.70, 3.04) 2.99 (1.41, 6.35)*
COPD-related inpatient visit (categorical) 1.29 (0.64, 2.61) 1.79 (0.84, 3.82)
COPD-related outpatient visit (categorical) 1.82 (1.44, 2.31)* 3.18 (2.28, 4.44)*
CIZ confidence interval; COPDZ chronic obstructive pulmonary disease; ERZ emergency room; GOLDZ Global Initiative for Chronic
Obstructive Lung Disease; ICD-9 Z International Classification of Diseases, 9th revision, Clinical Modification.
a The GOLD-Unclassified group was the reference category.
b p-values less than 0.05 are marked with asterisks.
c Obesity-related conditions were defined as ICD-9 codes for the following conditions: obesity, cholelithiasis (gallstones), osteoar-
thritis, low back pain, gastroesophageal reflux disease, obstructive sleep apnea, pulmonary embolism, and non-alcoholic fatty liver
disease.
d Short-acting b2-agonist Z levalbuterol, salbutamol; Long-acting b2-agonist Z formoterol, arformoterol, salmeterol; Short-acting
anticholinergics Z ipratropium bromide; Long-acting anticholinergics Z tiotropium; Combination short-acting b2-agonist plus anti-
cholinergic in one inhaler Z salbutamol/ipratropium; Inhaled glucocorticosteroids Z beclomethasone, budesonide, fluticasone pro-
pionate; Combination long-acting b2-agonist plus glucocorticosteroids Z formoterol/budesonide, salmeterol/fluticasone propionate;
Systemic glucocorticosteroids Z prednisone, methylprednisolone.
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Table 6 Evaluation of the multinomial logit prediction model of COPD severity.
Observed COPD severity category
GOLD-Unclassified Mild/Moderate Severe/Very Severe
Training sample (N Z 1824)
Predicted COPD severity category
GOLD-Unclassified 75.4% 43.2% 22.3% Correctly predicted 59.2%
Mild/Moderate 18.6% 44.3% 27.6% Kappa 0.35
Severe/Very Severe 6.0% 12.5% 50.1%
Sensitivity 75.4% 44.3% 50.1%
Specificity 65.2% 78.3% 91.1%
Accuracy 69.7% 66.9% 81.9%
Validation sample (N Z 204)
Predicted COPD severity category
GOLD-Unclassified 77.5% 33.3% 23.9% Correctly predicted 62.7%
Mild/Moderate 16.9% 52.2% 26.1% Kappa 0.41
Severe/Very Severe 5.6% 14.5% 50.0%
Sensitivity 77.5% 52.2% 50.0%
Specificity 70.4% 80.0% 90.5%
Accuracy 73.5% 70.6% 81.4%
COPD Z chronic obstructive pulmonary disease; GOLD Z Global Initiative for Chronic Obstructive Lung Disease.
1576 D. Macaulay et al.While this analysis involved a large database in which all
claims were captured, this study involves limitations of all
claims analyses, such as potential coding inaccuracies and
incomplete claims. COPD treatments may also change over
time. To mitigate this issue, we incorporated drugs into our
model at the class level. As new classes of COPD treatments
become available, our model would need to be updated to
incorporate these new drug classes. Further, we used the
GOLD classification of COPD severity available at the time
of the analysis to define severity. The most recent GOLD
severity definition also incorporates exacerbations, the
Modified Medical Research Council questionnaire (mMRC)
score for breathlessness, and the COPD Assessment Test
(CAT) score. While we did include COPD exacerbation as a
severity predictor, due to data limitations, we did not use
the new COPD severity definition, and developing a claims-
based prediction algorithm aligned with this new definition
is a subject for future study. Lastly, further study is needed
to assess the generalizability of this model to other patient
populations.
Conclusions
In this analysis, a COPD severity prediction model was
developed using spirometry and predictors typically avail-
able in claims data. The relevant predictors identified
included demographics, medical conditions, COPD-related
resource utilization, and all-cause healthcare visits. Using
claims data provides reliable information regarding health
utilization and comorbidities and provides a better pre-
diction model for use in future claims-based analyses.
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